Complete Characterization of Degradation Byproducts of Olmesartan Acid, Degradation Pathway, and Ecotoxicity Assessment

Giovanni Luongo, Antonietta Siciliano, Giovanni Libralato, Marco Guida, Lorenzo Saviano, Lucio Previtera, Giovanni Di Fabio and Armando Zarrelli

1. Introduction

Various analyses of wastewater show how the growth of the world’s population goes hand in hand with an increase in the concentration of organic micropollutants, such as perfluoroalkyl substances [1], cyanobacteria [2], mycotoxins [3], hormones [4], psychoactive substances [5], pesticides [6], cosmetics, and industrial additives and drugs [7–9], and demonstrate how this type of pollution reflects the increase in population growth [10,11]. Hence, there is a need to remove these pollutants present, especially in the most industrialized areas, from China to South Africa and from North and South America to Europe, wherever human activity presents significant developments [12,13]. The concentration of these pollutants, compared to traditional ones (conventional and unconventional), is much lower (on the order of ppm or ppb), and this characteristic has led to their classification as emerging contaminants (ECs) or persistent organic pollutants (POPs). There are no administrative regulations for environmental protection from this type of pollutant because its danger to the environment is not yet well understood. Despite the low concentrations, these are persistent and potentially toxic to microorganisms due to their complicated molecular structures, creating problems for the environment and humans. They can also be present in the water that is used to irrigate cultivation fields, even bringing the problem to the land...
and aquifers. Some have been identified in drinking water, consequently increasing the risk of these pollutants coming into contact with the human population [14]. Most of the pharmaceutical pollutants are introduced into the environment through people’s use of them who, failing to metabolize them completely, expel them into wastewater treatment processes that are not yet able to manage their removal. Other sources from which pharmaceutical pollutants come are hospitals, intensive livestock farming, and industrial waste [15]. The existing treatments used for the purification of wastewater do not currently guarantee the removal of ECs, which are degraded into less harmful compounds and only partially mineralized into inorganic substances. One of the ECs is olmesartan acid (OLM) [16], a hypertensive that is estimated to have an average daily consumption of almost 12 DDD per 1000 inhabitants (it was 3.7 in 2007), with a defined daily dose (DDD) value of 20 mg. In Italy alone, an expenditure of about EUR 150 million per year is estimated, almost five times more than the EUR 31 million in 2011 (it is among the top thirty active ingredients agreed upon for expenditure agreed by the national health system). It is marketed as olmesartan medoximil, the prodrug from which the active pharmaceutical is derived [17]. An excretion of 90% and a percentage of removal in wastewater treatment plants (WWTPs) not exceeding 20% are estimated for this drug. The simulation of the chlorination process in WWTP, which ensures the reduction of emerging pollutants, has allowed to study the degradation of OLM [18–23], leading to the isolation of nine degradation byproducts (DPs), eight of these are new (Figure 1) [24].

The aim of this work was to analyze the less abundant and more polar fractions that had been overlooked in previous studies, arriving at the determination of another 13 DPs, six of them isolated for the first time. All the DPs were identified by combining nuclear magnetic resonance (NMR) and mass spectrometry (MS), using matrix-assisted-laser desorption/ionization as a source and a time-of-flight analyzer (MALDI-TOF) for mass analysis. For all 22 isolated products, a formation mechanism has been proposed that integrates the one previously reported, having isolated and identified some products whose existence had only been hypothesized as possible intermediates. Finally, we evaluated the
acute and chronic toxicities of OLM and its twelve DPs on organisms from two levels of
the aquatic food chain, *Aliivibrio fischeri* bacteria and *Raphidocelis subcapitata* algae. Thus, it
is now possible to have an almost complete picture of the environmental fate of a EC found
in water bodies such as olmesartan, as a function of its intrinsic stability under the working
conditions of a WWTP, of the by-products obtained and their environmental impact.

2. Materials and Methods

2.1. Drug and Reagents

The chemicals for toxicity assessment and olmesartan acid (99.5%) were of analytical
grade and purchased from Sigma Aldrich (Milan, Italy). All the other chemicals and
solvents were supplied by Fluka (Saint-Quentin Fallavier, France) and were of HPLC grade
and used as received. Double-distilled water (Microtech, Naples, Italy) was used to prepare
the dilution water and treatments.

2.2. Chlorination Reaction

2.2.1. Apparatus and Equipment

Column chromatography (CC) was accomplished on Kieselgel 60 (40–63 µm, Merck,
Darmstadt, Germany). HPLC was performed on Shimadzu LC-8A system (Shimadzu,
Milan, Italy). GC was achieved on a Shimadzu 2010 series GC FID (Shimadzu, Milano, Italy).
The $^1$H- and $^{13}$C-NMR spectra were recorded with a 400 MHz NMR spectrometer (Bruker
DRX, Bruker Avance) referenced in ppm to the residual solvent signals (CDCl$_3$, at $\delta$H 7.27
and $\delta$C 77.0). Analysis of heteronuclear single-quantum coherence (HSQC), optimized
for $^1$J$_{HC}$ = 155 Hz, and heteronuclear multiple bond coherence (HMBC), optimized for
$n^1$J$_{HC}$ = 8 Hz, were used to measure the proton-detected heteronuclear correlations. The
MALDI TOF mass spectrometric analyses were performed on a Voyager-De Pro MALDI
mass-spectrometer (PerSeptive Biosystems, Framingham, MA, USA). The UV-Vis spectra
were run on a Perkin Elmer Lambda 7 spectrophotometer. The IR spectra were run on
a Jasco FT/IR-430 instrument equipped with a single reflection ATR accessory. pH was
recorded on a WTW pH 7110 pH-meter (Xylem Analytics, Weilheim, Germany) equipped
with a WTW SenTix41 electrode with temperature sensor.

2.2.2. Chlorination Experiments

The conditions used in a typical WWTP were simulated by treating a 10$^{-5}$ M OLM
solution with 10% hypochlorite (1:1 molar ratio of OLM/HClO by concentration, spectro-
scopically determined at $\lambda_{\text{max}}$ 292 nm, $\varepsilon$ 350 dm$^3$/mol cm) and 10$^{-3}$ M OLM solutions
with 10% hypochlorite (1:5 and 1:6 molar ratio of OLM/HClO by concentration, spectro-
scopically determined at $\lambda_{\text{max}}$ 292 nm, $\varepsilon$ 350 dm$^3$/mol cm) for 1 h at room temperature [25].
The presence of OLM was quantified using the UV-Vis spectrophotometer. The absorbance
peaks were evaluated at 230 nm. Using standard solutions with known OLM concentrations
it is possible to construct a calibration curve; then OLM concentrations were calculated
from absorbance peaks by interpolating the points on the corresponding calibration curve.
The pH of the solution is measured with the pH-meter; it passes from the initial value of
8.0 to the final value of 10.5. A small amount of the chlorinated solution was quenched by
an excess of sodium thiosulphate, filtered, dried by lyophilization; then the residue was sol-
ubilized in a saturated sodium bicarbonate solution and extracted with ethyl acetate (EA).
HPLC was used to monitor the course of the reaction. The main degradation byproducts
(DP10–DP17 for the EA fraction and DP18–DP22 for the aqueous fraction (W); Scheme 1
and Figure 2) were identified by comparing them with commercial reference compounds,
or isolated through preparative experiments with an OLM solution at concentration above
10$^{-3}$ M, using 6% hypochlorite at room temperature for 2 h. The proposed mechanism of
their formation and all other DPs previously isolated from the OLM is shown in Figure 3.
solution at concentration above $10^{-3}$ M, using 6% hypochlorite at room temperature for 2 h. The proposed mechanism of their formation and all other DPs previously isolated from the OLM is shown in Figure 3.

Figure 2. Chemical structures of olmesartan acid and its degradation byproducts DP10–DP22.

Figure 3. The plausible mechanism for the formation of DP1–DP17.
2.2.3. Chlorination Procedure and Product Isolation

Olmesartan acid (1 g, 2.24 mmol) was solubilized in 1.0 L of phosphate buffer (KH$_2$PO$_4$/K$_2$HPO$_4$ 0.1 M) [26]. A sodium hypochlorite solution (about 6% active chlorine, molar ratio OLM/HClO 1:20; concentration spectroscopically determined at $\lambda_{\text{max}}$ of 292 nm, $\varepsilon = 350$ dm$^3$/mol cm) was added drop by drop to this solution under magnetic stirring at room temperature. The phosphate buffer pH was adjusted to 6.50 by adding a 10% H$_3$PO$_4$ solution, checking with a pH-meter. Reaction was stopped after 2 h with an excess of sodium thiosulphate and concentrated by lyophilization. The residue was dissolved in water, pH is adjusted to 7.00, and this solution was extracted with ethyl acetate. The aqueous solution was subsequently extracted with $n$-butanol (B).

The crude EA fraction (579 mg) was chromatographed on silica gel CC, eluting with a gradient of methylene chloride:methanol:acetic acid (100:0:0.5 to 70:30:0.5, v/v/v) to yield sixteen fractions.

The fraction EA1 (26 mg), eluted with methylene chloride:methanol:acetic acid (100:0:0.5, v/v/v), was separated by semipreparative HPLC using a reversed-phase column Kromasil 10 $\mu$m 100 Å C18 (250 × 10 mm) and eluting with a gradient of CH$_3$COONH$_4$ (A, pH 4.0; 10 mM) and methanol (B), starting with 85% B for 1 min and using a gradient up to 100% B in 30 min, at a solvent flow rate of 2 mL/min, to yield DP10 and DP11 (3.1 and 1.3 mg, respectively).

The fraction EA6 (76 mg), eluted with methylene chloride:methanol:acetic acid (95:5:0.5, v/v/v), was analyzed via preparative HPLC using a reversed-phase Gemini column of 10 $\mu$m C18 110 Å (250 × 21 mm), eluting with a gradient of CH$_3$COONH$_4$ (A, pH 4.0; 10 mM) and acetonitrile (B), starting with 40% B for 1 min and using a gradient up to 100% B in 30 min, at a solvent flow rate of 7.5 mL/min to get five subfractions. The subfraction EA6.1 (33 mg) was re-chromatographed by HPLC using a reversed-phase Kinetex column of 2.6 $\mu$m 100 Å C18 (100 × 4.6 mm), eluting with a gradient of CH$_3$COONH$_4$ (A, pH 4.0; 10 mM) and acetonitrile (B), starting with 50% B for 1 min and using a gradient up to 100% B in 30 min, at a solvent flow rate of 0.8 mL/min, to get DP15 (2.1 mg). The subfraction EA6.2 (5 mg) was re-chromatographed by HPLC using a reversed-phase Kinetex column of 2.6 $\mu$m 100 Å C18 (100 × 4.6 mm) and eluting with a gradient of CH$_3$COONH$_4$ (A, pH 4.0; 10 mM) and acetonitrile (B), starting with 60% B for 5 min and using a gradient up to 100% B in 20 min, at a solvent flow rate of 1.0 mL/min. It contained DP16 (12.2 mg).

The fraction EA10 (51 mg), eluted with methylene chloride:methanol:acetic acid (85:15:0.5, v/v/v), was analyzed by semipreparative HPLC using a reversed-phase Gemini column of 10 $\mu$m C18 110 Å (250 × 10 mm) and eluting with a gradient of CH$_3$COONH$_4$ (A, pH 4.0; 10 mM) and methanol (B), starting with 35% B for 20 min, at a solvent flow rate of 4 mL/min, to yield four subfractions. The subfractions EA10.1 (7 mg) was re-chromatographed by HPLC using a reversed-phase Kinetex column of 2.6 $\mu$m 100 Å C18 (100 × 4.6 mm) and eluting with a gradient of acetic acid:acetonitrile (A, 1:99, v/v) and acetic acid:water (B, 1:99, v/v), starting with 75% B for 3 min and installing a gradient to obtain 100% A over 35 min and returning to 75% B for 10 min, at a solvent flow rate of 0.8 mL/min. It contained DP13 (3.2 mg). The subfractions EA10.4 (16 mg) was re-chromatographed by HPLC using a reversed-phase Kinetex column of 2.6 $\mu$m 100 Å C18 (100 × 4.6 mm) and eluting with a gradient of acetic acid:acetonitrile (A, 1:99, v/v) and acetic acid:water (B, 1:99, v/v), starting with 60% B for 5 min and using a gradient up to 100% A in 20 min and returning to 60% B for 10 min, at a solvent flow rate of 1.0 mL/min. It contained DP16 (12.2 mg).

The fraction obtained by extraction with $n$-butanol (B, 635 mg) was again fractioned by silica gel CC, using a gradient of ethyl acetate:methanol, to give six fractions. The B5 fraction (12 mg), eluted with ethyl acetate:methanol (50:50, v/v), was dried, solubilized in water:ethanol (50:50, v/v), and analyzed using a Shimadzu 2010 series GC FID (Shimadzu, Milano, Italy). The gas chromatograph was equipped with Zebron ZB-5 column (30 m × 0.32 mm I. D., 1.00 $\mu$m; Phenomenex, Bologna, Italy). The following parameters were set
The aqueous fraction (W, 711 mg) was dried by lyophilization, re-dissolved in methanol and separated with CC silica gel by running an ethyl acetate:methanol gradient (100:0 to 0:100, v/v) to get eight fractions.

The fraction W2 (155 mg), eluted with ethyl acetate:methanol (60:40, v/v), was filtered on reversed phase silica gel CC with water, methanol, and acetonitrile. The fraction eluted with acetonitrile (6 mg) was analyzed by NMR and contained DP20.

The fraction W7 (187 mg), eluted with ethyl acetate:methanol (50:50, v/v), was chromatographed on a reversed phase Sep-Pak RP-18 with a gradient of acetic acid 1%:acetonitrile (100:0 to 0:100 v/v). The fraction eluted with acetic acid 1% was concentrated by lyophilization (31 mg), analyzed by HPLC using a reversed-phase Luna column of 5 μm C8(2) 100 Å (150 × 4.6 mm), and eluted with an isocratic solution of KH₂PO₄ (pH 2.6, 20 mM):acetonitrile (75:25 v/v) at a solvent flow rate of 1 mL/min. It contained DP21, as evidenced by the RT comparison with a standard compound and NMR spectra. The fraction eluted with acetonitrile was analyzed by HPLC using a reversed-phase Luna column of 5 μm Phenyl-Hexyl 100 Å (150 × 4.6 mm) and eluting with water (A) and acetonitrile (B), starting with 40% B for 10 min and later obtaining 55% B over 10 min, at a solvent flow rate of 1.2 mL/min. It contained DP22, as evidenced by the RT comparison with a standard compound and NMR spectra.
2.3. Spectral Data

DP10: 2-(1-((2′-(2H-Tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-5-chloro-2-propyl-1H-imidazol-4-yl)propan-2-ol. White powder. $^1$H- and $^{13}$C-NMR: see Table S1. MS-TOF (positive ions): $m/z$ calculated for $C_{23}H_{25}ClN_5O_2$ $m/z$ 436.18 [M $^+$]; found 439.22 [M + 2 + H]$^+$ (30%), 438.19 [M + 1 + H]$^+$ (23%), 437.19 [M + H]$^+$ (90%).

DP11: N-((2′-(2H-Tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)butyramide. $^1$H- and $^{13}$C-NMR: see Table S2. MS-TOF (positive ions): $m/z$ calculated for $C_{18}H_{19}N_5O$ $m/z$ 321.16 [M $^+$]; found 322.18 [M + H]$^+$ (58%), 252.17 [M–COCH$_3$+H]$^+$ (30%).

DP12: N-((2′-(2H-Tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-hydroxymethylbutanamide. $^1$H- and $^{13}$C-NMR: see Table S3. MS-TOF (positive ions): $m/z$ calculated for $C_{18}H_{19}N_5O_2$ $m/z$ 337.15 [M $^+$]; found 338.17 [M + H]$^+$ (51%), 319.16 [M–H$_2$O]$^+$ (15%).

DP13: ((2′-(2H-Tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)(acetyl)carbamic acid. $^1$H- and $^{13}$C-NMR: see Table S4. MS-TOF (positive ions): $m/z$ calculated for $C_{17}H_{15}N_5O_3$ $m/z$ 337.15 [M $^+$]; found 338.16 [M + H]$^+$ (29%), 294.17 [M–CO$_2$+H]$^+$ (11%).

DP14: N-((2′-(2H-Tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)acetamide. $^1$H- and $^{13}$C-NMR: see Table S5. MS-TOF (positive ions): $m/z$ calculated for $C_{16}H_{15}N_5O$ $m/z$ 293.13 [M $^+$]; found $m/z$ 294.14 [M + H]$^+$ (55%), 250 [M–CO$_2$+H]$^+$ (22%).

DP15: N-((2′-(2H-Tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)hydroxylamine. $^1$H- and $^{13}$C-NMR: see Table S6. MS-TOF (positive ions): $m/z$ calculated for $C_{14}H_{13}N_5O$ $m/z$ 267.11 [M $^+$]; found $m/z$ 268.12 [M + H]$^+$ (29%).

DP16: 2′-(2H-Tetrazol-5-yl)-[1,1′-biphenyl]-4-carboxylic acid. NMR spectra were in agreement with data reported in the literature [27].

DP17: (2′-(2H-Tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methanamine. NMR spectra were in agreement with data reported in the literature [28].

DP18: Butyric acid. White powder. NMR spectra conform to data recorded for the available standard.

DP19: Butyramide. White liquid. Chemical-physical properties conforming to data recorded for the available standard.

DP20: Butyronitrile. White liquid. Chemical-physical properties conforming to data recorded for the available standard.

DP21: Chlorobenzene. White liquid. Chemical-physical properties conforming to data recorded for the available standard.

DP22: Benzoic acid. White solid. Chemical-physical properties conforming to data recorded for the available standard.

2.4. Toxicity Tests

Toxicity tests were performed on OLM and its DPs were isolated from chlorination experiments at initial concentrations of 5 mg/L. Acute toxicity was carried out on A. fischeri (NRRLB-11177) bacterium supplied by MicroBioTest, Belgium, according to ISO 11348-3:2007. The bioluminescence inhibition test was performed as previously described [24]. OLM and its DPs were tested in three replicates, and the inhibitory effect was measured after 30 min of exposure. Chronic toxicity tests were carried out on R. subcapitata and were performed in 24-well microplates according to Gallo et al. [29]. The algal inoculum was taken from an exponentially growing culture according to ISO 8692 [30], and it was added to OLM and its DPs to reach a final algal concentration of 10$^4$ cells/mL. Compounds were tested in three replicates. The algal growth was measured after 72 h at 670 nm (HachLange DR 5000). The acute and chronic results were processed using Prism 8 (GraphPad Inc., Version 8.4.2, San Diego, CA, USA) and analyzed statistically using ANOVA and the Tukey post hoc test, with $p < 0.05$ considered to be significantly different.

3. Results and Discussion

3.1. Chlorination Experiments

The OLM chlorination experiments were performed by mimicking the conditions of a typical WWTP. A 10$^{-5}$ M solution of the drug was treated for 1 h with 10% hypochlorite.
(OLM: hypochlorite molar ratio of 1:1; concn.) at room temperature [31,32]. Then, the OLM chlorination experiments were repeated by treating $10^{-3}$ M with a much lower ratio of OLM:oxidizing agent (1:5 or 1:6) so as to ensure the degradation of the studied contaminant and the possibility of isolating sufficient quantities of degradation byproducts for their subsequent structural identification. The course of the reaction was monitored by HPLC, and the DPs obtained were isolated by column chromatography, HPLC, and GC (Scheme 1) and completely characterized using NMR (see Supplementary Materials) and MS analyses. DP10–DP17 were isolated in relative percentages of 0.31, 0.13, 0.14, 0.32, 0.11, 0.21, 1.22, and 1.34, respectively. The proposed mechanism of their formation from OLM is displayed in Figure 3. DP10–DP15 were isolated for the first time. The quantity of OLM recovered after chromatography of the initial extract of the chlorinated solution and its identification by comparison with an authentic commercial sample allowed to evaluate a percentage of mineralization around 59% under the specified conditions, while the formation of DPs is around 20%.

3.2. Structure Elucidation of Degradation Byproducts DP1–DP22

In the OLM treatment at the buffered pH, the concentration of DP10–DP17 was at a maximum after 1 h, in the range of 1.34 to 0.11%, while that of DP18–DP22 was at a maximum after 2.5 h. The possible mechanisms underlying the formation of OLM by products is shown in Figure 3. OLM can undergo the imidazole ring opening reaction with the cleavage of the N19-C23 and C20-N21 bonds, obtaining the DP11 product. This could undergo an oxidation to the carbon of the side chain (which, in the starting product, was indicated as carbon C-24), producing the DP12 product. Luongo et al. [24] hypothesized that DP11 and DP12 could be two intermediates, which, through a third intermediate I15, would lead to the degradation of DP8 byproducts. From this, then, by reductive decarboxylation, the obtaining of the DP15 product is justified, which would then provide DP16 by deamination of the side chain and oxidation of the C-18 carbon to a carboxyl group. From DP12, it is easy to justify the formation of DP17 by hydrolysis of the N19-C20 bond. The degradation of the DP17 byproduct by oxidation would give DP15 by acetylation of DP14 and by subsequent oxidation of this, the DP13 product. Finally, the DP18–DP22 products are degradation products that can be justified in different ways and that constitute the step preceding the complete mineralization of the starting product.

3.3. Ecotoxicity Data

The inhibition effects on the bioluminescence of A. fischeri and on the growth of R. subcapitata were measured in this section for characterizing the acute and chronic toxicity of DPs at concentrations of 5 mg/L. Figure 4 shows the comparison of the effects of DPs.

Only in three DPs (DP14, DP20, and DP22) in R. subcapitata and two DPs in A. fischeri (DP14 and DP20) the stimulation was observed, showing no toxic effects. However, in 75% of the DPs investigated, the negative effects increased compared to the parent compound (OLM). In particular, the bioluminescence inhibition of the A. fischeri in DP16 exceeded 70%. The acute toxicity in each DPs followed the order of DP14 > DP20 > DP21 > DP15 > DP22 > DP11 > DP10 > DP12 > DP18 > DP19 > DP13 > DP16, while the chronic toxicity in each DPs followed the order of DP22 > DP20 > DP14 > DP13 > DP18 > DP15 > DP19 > DP12 > DP21 > DP11 > DP10 > DP16. Considering the overall toxicity, these results demonstrate that higher inhibitory values, especially for A. fischeri, were achieved for DP16, while lower inhibitory values were achieved for DP20. Thus, as a strong oxidant, sodium hypochlorite could decompose non-toxic OLM into small molecules, increasing the toxicity of the compound. Although the concentrations investigated and capable of exerting toxic effects may be higher than the environmental concentrations, the possible problems due to continued exposure, which can occur through contact with water and through the food chain, should not be underestimated.
Supplementary Materials: $^1$H and $^{13}$CNMR data of DP10–DP15 are available online at https://www.mdpi.com/article/10.3390/app1125393/s1 in Tables S1–S6.

Author Contributions: G.L. (Giovanni Luongo) performed the chlorination experiments; M.G., A.S., G.L. (Giovanni Libralato) and L.S. performed the acute and chronic toxicity tests; L.P. and G.D.F. were responsible for supervision, writing, review, and editing; A.Z. designed the research study and was responsible for supervision, original draft preparation, and writing the final version of manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We acknowledge AIPRAS Onlus (Associazione Italiana per la Promozione delle Ricerche sull’Ambiente e la Saluta umana) for grants in support of this investigation.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ahrens, L.; Bundschuh, M. Fate and effects of poly- and perfluoroalkyl substances in the aquatic environment: A review. *Environ. Toxicol. Chem.* 2014, 33, 1921–1929. [CrossRef]

2. Blaha, L.; Babica, P.; Maršálek, B. Toxins produced in cyanobacterial water blooms—Toxicity and risks. *Interdiscip. Toxicol.* 2009, 2, 36–41. [CrossRef]
3. Mata, A.T.; Ferreira, J.P.; Oliveira, B.R.; Batoréu, M.C.; Crespo, M.T.B.; Pereira, V.J.; Bronze, M.R. Bottled water: Analysis of mycotoxins by LC–MS/MS. Food Chem. 2015, 176, 455–464. [CrossRef]

4. Gensiorowski, A.; Mouriokes, V.E.; Flaws, J.A. Endocrine Disruptors in Water and Their Effects on the Reproductive System. Int. J. Mol. Sci. 2020, 21, 1929. [CrossRef]

5. Ebele, A.J.; Abdallah, M.A.-E.; Harrad, S. Pharmaceuticals and personal care products (PPCPs) in the freshwater aquatic environment. Emerg. Contam. 2017, 3, 1–16. [CrossRef]

6. Calderón-Preciado, D.; Matamoros, V.; Bayona, J.M. Occurrence and potential crop uptake of emerging contaminants and related compounds in an agricultural irrigation network. Sci. Total. Environ. 2011, 412, 14–19. [CrossRef] [PubMed]

7. Abdemi, B.L.; James, O.A.; Oluwatosin, A.T.; Akinropo, O.J.; Oraeuloka, U.D.; Racheal, A.E. Treatment technologies for wastewater from cosmetic industry—A review. Int. J. Chem. Biomol. 2018, 4, 69–80.

8. Fonseca, V.F.; Duarte, I.A.; Duarte, B.; Freitas, A.; Pouca, A.S.V.; Barbosa, J.; Gillanders, B.M.; Reis-Santos, P. Environmental risk assessment and bioaccumulation of pharmaceuticals in a large urbanized estuary. Sci. Total. Environ. 2021, 783, 147021. [CrossRef] [PubMed]

9. Mijangos, L.; Ziarrusta, H.; Ros, O.; Kortazar, L.; Fernández, L.A.; Olivares, M.; Zuloaga, O.; Prieto, A.; Etxebarria, N. Occurrence of emerging pollutants in estuaries of the Basque Country: Analysis of sources and distribution, and assessment of the environmental risk. Water Res. 2018, 147, 152–163. [CrossRef]

10. Burns, E.E.; Carter, L.J.; Kolpin, D.W.; Thomas-Oates, J.; Boxall, A.B. Temporal and spatial variation in pharmaceutical concentrations in an urban river system. Water Res. 2018, 137, 72–85. [CrossRef]

11. Lesser, L.E.; Mora, A.; Moreau, C.; Mahlknecht, J.; Hernández-Antonio, A.; Ramírez, A.I.; Barrios-Piña, H. Survey of 218 organic contaminants in groundwater derived from the world’s largest untreated wastewater irrigation system: Mezquital Valley, Mexico. Chemosphere 2018, 198, 510–521. [CrossRef]

12. Ma, R.; Wang, B.; Yin, L.; Zhang, Y.; Deng, S.; Huang, J.; Wang, Y.; Yu, G. Characterization of pharmaceutically active compounds in Beijing, China: Occurrence pattern, spatiotemporal distribution and its environmental implication. J. Hazard. Mater. 2017, 323, 147–155. [CrossRef]

13. Verhaert, V.; Newmark, N.; D’Hollander, W.; Covaci, A.; Vlok, W.; Wepener, V.; Addo-Bediako, A.; Jooste, A.; Teuchies, J.; Blust, R.; et al. Persistent organic pollutants in the Olifants River Basin, South Africa: Bioaccumulation and trophic transfer through a subtropical aquatic food web. Sci. Total. Environ. 2017, 586, 792–806. [CrossRef]

14. Luo, Y.; Guo, W.; Ngo, H.H.; Nghiem, L.D.; Hai, F.I.; Zhang, J.; Liang, S.; Wang, X.C. A review on the occurrence of micropollutants in the aquatic environment and their fate and removal during wastewater treatment. Sci. Total. Environ. 2014, 473, 619–641. [CrossRef]

15. De la Cruz, N.; Esquius, L.; Grandjean, D.; Magnet, A.; Tungler, A.; de Alencastro, L.F.; Pulgarín, C. Degradation of emergent contaminants by UV, UV/H2O2 and neutral photo-Fenton at pilot scale in a domestic wastewater treatment plant. Water Res. 2013, 47, 5836–5845. [CrossRef] [PubMed]

16. Bayer, A.; Asner, R.; Schüssler, W.; Kopf, W.; Weiß, K.; Sengl, M.; Letzel, M. Behavior of sartans (antihypertensive drugs) in wastewater treatment plants, their occurrence and risk for the aquatic environment. Sci. Total. Environ. 2018, 510–521. [CrossRef] [PubMed]

17. Schwabe, U.; Paffrath, D. Report on Pharmaceutical Prescriptions; Springer: Berlin, Germany, 2013. (In German)

18. Zarrelli, A.; della Greca, M.; Jesce, M.R.; Lavorgna, M.; Temussi, F.; Schiavone, L.; Crespo, M.T.B.; Farrera, A.; Previtera, L.; Isidori, M. Ecotoxicological evaluation of caffeine and its derivatives from a simulated chlorination step. Sci. Total. Environ. 2014, 470, 453–458. [CrossRef] [PubMed]

19. Chusakri, S.; Suththivaiyakit, S.; Sutthivaiyakit, P. Reactions of phenylurea compounds with aqueous chlorine: Implications for herbicide transformation during drinking water degradation. J. Hazard. Mater. 2012, 209, 484–491. [CrossRef]

20. Romanucci, V.; Siciliano, A.; Guida, M.; Libralato, G.; Saviano, L.; Luongo, G.; Previtera, L.; di Fabio, G.; Zarrelli, A. Disinfection by-products and ecotoxic risk associated with hypochlorite treatment of ibesartan. Sci. Total. Environ. 2020, 712, 135625. [CrossRef] [PubMed]

21. Sandin-España, P.; Magrans, J.O.; García-Baudín, J.M. Study of Cethodim Degradation and By-Product Formation in Chlorinated Water by HPLC. Chromatography 2005, 62, 133–137. [CrossRef]

22. Luongo, G.; Previtera, L.; Ladhari, A.; di Fabio, G.; Zarrelli, A. Peracetic Acid vs. Sodium Hypochlorite: Degradation and Transformation of Drugs in Water. Molecules 2020, 25, 2294. [CrossRef] [PubMed]

23. Luongo, G.; Guida, M.; Siciliano, A.; Libralato, G.; Saviano, L.; Amoresano, A.; Previtera, L.; di Fabio, G.; Zarrelli, A. Oxidation of diclofenac in water by sodium hypochlorite: Identification of new degradation by-products and their ecotoxicological evaluation. J. Pharm. Biomed. Anal. 2021, 194, 113762. [CrossRef] [PubMed]

24. Luongo, G.; Siciliano, A.; Libralato, G.; Serafini, S.; Saviano, L.; Previtera, L.; di Fabio, G.; Zarrelli, A. LC and NMR Studies for Identification and Characterization of Degradation Byproducts of Olmesartan Acid, Elucidation of Their Degradation Pathway and Ecotoxicity Assessment. Molecules 2021, 26, 1769. [CrossRef] [PubMed]

25. Bedner, M.; MacCrehan, W.A. Transformation of Acetaminophen by Chlorination Produces the Toxictants 1,4-Benzoquinone and N-Acetyl-p-benzoquinone Imine. Environ. Sci. Technol. 2006, 40, 516–522. [CrossRef]

26. Carpinteiro, L.; Castro, G.; Rodríguez, I.; Cela, R. Free chlorine reactions of angiotensin II receptor antagonists: Kinetics study, transformation products elucidation and in-silico ecotoxicity assessment. Sci. Total. Environ. 2019, 647, 1000–1010. [CrossRef]
27. Nödler, K.; Hillebrand, O.; Idzik, K.; Strathmann, M.; Schiperski, F.; Zirlewagen, J.; Licha, T. Occurrence and fate of the angiotensin II receptor antagonist transformation product valsartan acid in the water cycle—A comparative study with selected β-blockers and the persistent anthropogenic wastewater indicators carbamazepine and acesulfame. *Water Res.* 2013, 47, 6650–6659. [CrossRef]

28. Mutha, V.A.K.; Guduru, S.; Kaliyaperumal, M.; Rumalla, C.S.; Maddi, S.R.; Korupolu, R.B.; Gajbhiye, S.B. Disinfection study of irbesartan: Isolation and structural elucidation of novel degradants. *J. Pharm. Biomed. Anal.* 2018, 157, 180–188. [CrossRef]

29. Gallo, A.; Guida, M.; Armiento, G.; Siciliano, A.; Mormile, N.; Carraturo, F.; Pellegrini, D.; Morroni, L.; Tosti, E.; Ferrante, M.; et al. Species-specific sensitivity of three microalgae to sediment elutriates. *Mar. Environ. Res.* 2020, 156, 104901. [CrossRef]

30. ISO. *Water Quality—Fresh Water Algal Growth Inhibition Test with Unicellular Green Algae*; ISO: Geneva, Switzerland, 2012; ISO 8692.

31. Romanucci, V.; Siciliano, A.; Galdiero, E.; Guida, M.; Luongo, G.; Liguori, R.; di Fabio, G.; Previtera, L.; Zarrelli, A. Degradation by-Products and Ecotoxic Risk Associated with Hypochlorite Treatment of Tramadol. *Molecules* 2019, 24, 693. [CrossRef]

32. Zarrelli, A.; della Greca, M.; Parolisi, A.; Iesce, M.R.; Cermola, F.; Temussi, F.; Isidori, M.; Lavorgna, M.; Passananti, M.; Previtera, L. Chemical fate and genotoxic risk associated with hypochlorite treatment of nicotine. *Sci. Total. Environ.* 2012, 426, 132–138. [CrossRef]